Juno Therapeutics
| Company type | Subsidiary |
|---|---|
| Nasdaq: JUNO | |
| Industry | Biotechnology |
| Founded | 2013 |
| Headquarters | Seattle, Washington |
Key people | |
| Parent | Bristol-Myers Squibb |
| Website | www |
Juno Therapeutics, Inc. was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.
On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion.
In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene.